Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey
- PMID: 10884256
- PMCID: PMC27426
- DOI: 10.1136/bmj.321.7253.78
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey
Abstract
Objectives: To determine the prevalence of antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in the prison population of the Republic of Ireland and to examine risk factors for infection.
Design: Cross sectional, anonymous, unlinked survey, with self completed risk factor questionnaire and provision of oral fluid specimen for antibody testing.
Setting: Nine of the 15 prisons in the Republic of Ireland.
Participants: 1366 prisoners, of whom 1205 (57 women) participated. In the smaller prisons all prisoners were surveyed, while in the three largest prisons one half of the population was randomly sampled. Three small prisons believed not to have a problem with injecting drug use were excluded.
Main outcome measures: Prevalence of antibodies to hepatitis B core antigen, antibodies to hepatitis C virus, and antibodies to HIV. Self reported risk factor status.
Results: Prevalence of antibodies to hepatitis B core antigen was 104/1193 (8.7%; 95% confidence interval 7.2% to 10.5%), to hepatitis C virus, 442/1193 (37%; 34.3% to 39.9%), and to HIV, 24/1193 (2%; 1.3% to 3%). The most important predictor of being positive for hepatitis B and hepatitis C was a history of injecting drug use. Thirty four women (60%) and 474 men (42%) reported ever injecting drugs. A fifth (104) of 501 injecting drug users reported first injecting in prison, and 347 (71%) users reported sharing needles in prison.
Conclusions: Infection with hepatitis C secondary to use of injected drugs is endemic in Irish prisons. Better access to harm reduction strategies is needed in this environment.
Comment in
-
Health effects of prisons. Many injectors stop injecting while imprisoned.BMJ. 2000 Dec 2;321(7273):1406. BMJ. 2000. PMID: 11099291 Free PMC article. No abstract available.
-
Health effects of prisons. Risks of syringe exchange programmes in prisons prevail.BMJ. 2000 Dec 2;321(7273):1406-7. BMJ. 2000. PMID: 11099292 No abstract available.
-
Health effects of prisons. Properly executed vaccination programme might minimise harm.BMJ. 2000 Dec 2;321(7273):1407. BMJ. 2000. PMID: 11099293 No abstract available.
-
Health effects of prisons. Legitimacy of punishment systems should be addressed.BMJ. 2000 Dec 2;321(7273):1407. BMJ. 2000. PMID: 11099294 Free PMC article. No abstract available.
References
-
- Malliori M, Sypsa V, Psichogiou M, Touloumi G, Skoutelis A, Tassopoulos N, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 1998;93:243–251. - PubMed
-
- Rotily M, Galinier-Pujol A, Vernay-Vaisse C. Risk behaviours of inmates in south-eastern France. AIDS Care. 1995;7(suppl 1):89–93. - PubMed
-
- O'Mahony P. Mountjoy prisoners: a sociological and criminological profile. Dublin: Stationery Office; 1997.
-
- Dolan K, Hall W, Wodak A. The provision of methadone within prison settings. In: Ward J, Mattick RP, Hall W, editors. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic; 1998. pp. 379–395.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical